/
We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on our proprietary arenavirus platform that is designed to target and amplify T cell and immune responses to fight diseases. Our replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.
The business is unprofitable at the operating level (-117.09% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 118.3% YoY with margins expanding 368.3pp.
Negative free cash flow of -$77M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$9M
▲ +118.3% YoY
Net Income (TTM)
-$73M
▲ +46.7% YoY
Op. Margin
-860.18%
▲ +368.3pp YoY
ROIC
-100.73%
▲ +20.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$53M
▼ -25.1% YoY
Op. Cash Flow (TTM)
-$53M
▼ -33.8% YoY
Net Debt
-$40M
Net Cash Position
Cash & Equiv.
$40M
5Y CAGR: +29.8%
Continue Research